AP-2β Inhibitors
The chemical class known as AP-2β inhibitors comprises a diverse array of compounds targeting various signaling pathways and cellular processes intricately linked to the modulation of AP-2β activity. Geldanamycin, Mitoxantrone, and PD98059 directly inhibit AP-2β by disrupting its interactions with Hsp90, inducing cell cycle arrest, and affecting the MAPK pathway, respectively. SB203580, SP600125, and U0126 indirectly inhibit AP-2β by targeting the p38 MAPK and JNK pathways, illustrating the complex regulatory network influencing AP-2β. LY294002, Sorafenib, and AZD5363 directly inhibit AP-2β by disrupting the PI3K/Akt pathway, highlighting the significance of this pathway in the context of AP-2β-mediated processes. BI-D1870 and SB431542 serve as specific inhibitors by disrupting Polo-like kinase and TGF-β signaling, respectively, providing insights into the diverse mechanisms through which AP-2β is regulated. NG25, a dual TAK1 and MAP4K2 inhibitor, directly impacts the TAK1 pathway, showcasing its role in modulating AP-2β activity.
This comprehensive overview emphasizes the intricate network of signaling pathways and cellular processes converging on AP-2β and provides a foundation for understanding the molecular mechanisms underlying its regulation. The specificity of these inhibitors in influencing defined pathways offers valuable insights into potential strategies for precise cellular control in the context of AP-2β-mediated processes. The diverse array of compounds highlights the complexity of AP-2β regulation and provides a roadmap for further exploration of targeted chemical interventions in the regulatory network governing the activity of this transcription factor.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
Geldanamycin, an Hsp90 inhibitor, disrupts the Hsp90 chaperone function. AP-2β is known to interact with Hsp90, and Geldanamycin inhibits this interaction, leading to degradation of AP-2β. | ||||||
Mitoxantrone | 65271-80-9 | sc-207888 | 100 mg | $279.00 | 8 | |
Mitoxantrone, a topoisomerase II inhibitor, directly affects DNA replication. AP-2β has been associated with the regulation of cell cycle genes, and by inhibiting topoisomerase II, Mitoxantrone disrupts DNA replication and induces cell cycle arrest, indirectly inhibiting AP-2β. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059, a MEK inhibitor, affects the MAPK pathway. As AP-2β is involved in the MAPK pathway-mediated signaling, PD98059 indirectly inhibits AP-2β by preventing the activation of downstream targets. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580, a p38 MAPK inhibitor, targets the p38 MAPK pathway. AP-2β has been linked to p38 MAPK signaling, and by inhibiting p38 MAPK, SB203580 indirectly inhibits AP-2β. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125, a JNK inhibitor, directly affects the JNK pathway. As AP-2β is intricately connected to JNK-mediated pathways, SP600125 serves as a key inhibitor of AP-2β. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002, a reversible PI3-kinase inhibitor, directly interferes with the PI3K/Akt pathway. As AP-2β is connected to the PI3K/Akt pathway, LY294002 serves as an inhibitor by disrupting the phosphorylation cascade critical for downstream signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, targets various kinases involved in cell proliferation and survival. AP-2β has been associated with these processes, and Sorafenib serves as an inhibitor by blocking multiple signaling pathways. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, directly targets the PI3K/Akt pathway. As AP-2β is intricately connected to the PI3K/Akt pathway, AZD5363 serves as an inhibitor by disrupting the phosphorylation events critical for downstream signaling. | ||||||
BI-D1870 | 501437-28-1 | sc-397022 sc-397022A | 1 mg 5 mg | $90.00 $275.00 | 12 | |
BI-D1870, a selective PLK inhibitor, directly targets Polo-like kinase (PLK), which plays a role in the cell cycle. AP-2β is connected to cell cycle regulation, and BI-D1870 serves as a specific inhibitor by disrupting PLK-mediated processes. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $80.00 $212.00 $408.00 | 48 | |
SB431542, a TGF-β receptor inhibitor, directly impacts the TGF-β signaling pathway. Since TGF-β signaling is intricately connected to AP-2β-mediated processes, SB431542 serves as a key inhibitor of AP-2β. | ||||||